Trevi Therapeutics Inc [NASDAQ: TRVI] closed the trading session at $8.0 on 2025-08-27. The day’s price range saw the stock hit a low of $7.37, while the highest price level was $8.78.
The stocks have a year to date performance of 167.56 percent and weekly performance of 7.82 percent. The stock has been moved at 77.38 percent over the last six months. The stock has performed 5.96 percent around the most recent 30 days and changed 27.80 percent over the most recent 3-months.
If compared to the average trading volume of 1.94M shares, TRVI reached to a volume of 9485682 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Trevi Therapeutics Inc [TRVI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TRVI shares is $19.58 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TRVI stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Trevi Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on August 21, 2025. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on July 01, 2025, representing the official price target for Trevi Therapeutics Inc stock. Previously, the target price had yet another raise to $21, while H.C. Wainwright analysts kept a Buy rating on TRVI stock. On March 10, 2025, analysts increased their price target for TRVI shares from 9 to 29.
The Price to Book ratio for the last quarter was 4.91, with the Price to Cash per share for the same quarter was set at 1.67.
TRVI stock trade performance evaluation
Trevi Therapeutics Inc [TRVI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.82. With this latest performance, TRVI shares gained by 5.96% in over the last four-week period, additionally plugging by 77.38% over the last 6 months – not to mention a rise of 94.17% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TRVI stock in for the last two-week period is set at 66.00, with the RSI for the last a single of trading hit 0.45, and the three-weeks RSI is set at 0.41 for Trevi Therapeutics Inc [TRVI]. The present Moving Average for the last 50 days of trading for this stock 6.88, while it was recorded at 7.55 for the last single week of trading, and 5.42 for the last 200 days.
Trevi Therapeutics Inc (TRVI) Capital Structure & Debt Analysis
According to recent financial data for Trevi Therapeutics Inc. ( TRVI), the Return on Equity (ROE) stands at -35.74%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -33.53%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Trevi Therapeutics Inc’s Return on Invested Capital (ROIC) is -23.76%, showcasing its effectiveness in deploying capital for earnings.
Trevi Therapeutics Inc (TRVI) Efficiency & Liquidity Metrics
Based on Trevi Therapeutics Inc’s (TRVI) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Trevi Therapeutics Inc (TRVI) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Trevi Therapeutics Inc. (TRVI) effectively leverages its workforce, generating an average of -$1819230.77 per employee. The company’s liquidity position is robust, with a Current Ratio of 22.42% and a Quick Ratio of 22.42%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Trevi Therapeutics Inc [TRVI] stock
With the latest financial reports released by the company, Trevi Therapeutics Inc posted -0.13/share EPS, while the average EPS was predicted by analysts to be reported at -0.11/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.02. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TRVI. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Trevi Therapeutics Inc go to -11.43%.
Trevi Therapeutics Inc [TRVI]: Institutional Ownership
There are presently around $92.72%, or 93.39%% of TRVI stock, in the hands of institutional investors. The top three institutional holders of TRVI stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 11.37 million shares, which is approximately 11.2532%. FRAZIER LIFE SCIENCES MANAGEMENT, L.P., holding 7.38 million shares of the stock with an approximate value of $$22.0 million in TRVI stocks shares; and FRAZIER LIFE SCIENCES MANAGEMENT, L.P., currently with $$14.98 million in TRVI stock with ownership which is approximately 4.9751%.
